⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405930 | 0.82 | — | — | |
| SCHEMBL8909834 | 0.79 | MEN1 (0.35) | — | |
| SCHEMBL3321683 | 0.75 | — | — | |
| SCHEMBL5715676 | 0.73 | MEN1 (0.32) | — | |
| SCHEMBL736157 | 0.73 | — | — | |
| SCHEMBL24424824 | 0.71 | CA12 (0.44) | — | |
| SCHEMBL1043900 | 0.71 | — | — | |
| SCHEMBL8579206 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL21955607 | 0.71 | HTR2A (0.31) | — | |
| SCHEMBL2737210 | 0.71 | CA12 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | claimed |
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | claimed |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2021-05-13 | — | — | US | claimed |
| EP-2824105-B1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2021-03-31 | — | — | EP | claimed |
| CN-106083855-B | Purine derivatives useful as Hsp90 inhibitors | 斯隆-凯特林癌症研究院 | 2020-04-10 | — | — | CN | claimed |
| EP-3208615-B1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-10-09 | — | — | EP | claimed |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-07-02 | — | — | US | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-01-08 | — | — | US | claimed |
| CN-106083855-A | Purine derivative as Hsp90 inhibitor | 斯隆-凯特林癌症研究院 | 2016-11-09 | — | — | CN | claimed |
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | 4SC AG (DE) | 2011-02-03 | — | — | US | claimed |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-03 | — | — | US | claimed |
| EP-2034839-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | Sloan-Kettering Institute For Cancer Research (US) | 2009-03-18 | — | — | EP | claimed |
| CN-101389628-A | Indolopyridines as EG5 kinesin modulators | 4SC AG (DE) | 2009-03-18 | — | — | CN | claimed |
| CN-101389629-A | Indolopyridines as EG5 kinesin modulators | 4SC AG (DE) | 2009-03-18 | — | — | CN | claimed |
| EP-2033962-A1 | Tetracyclic indolopyridines as EG5 inhibitors | 4SC AG (DE) | 2009-03-11 | — | — | EP | claimed |
| WO-2008005937-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-01-10 | — | — | WO | claimed |
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | claimed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | claimed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | claimed |